{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T19:34:21Z","timestamp":1781379261903,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,9]]},"DOI":"10.7759\/cureus.71142","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:17:24Z","timestamp":1728487044000},"source":"Crossref","is-referenced-by-count":2,"title":["Hydrogel Matrix Containing Microcarriers for Dexamethasone Delivery to Protect Against Cisplatin-Induced Hearing Loss"],"prefix":"10.7759","author":[{"given":"Maximilian G","family":"Dindelegan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina M","family":"Blebea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Perde-Schrepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Necula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma A","family":"Maniu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Pascalau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Popa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Susman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana M","family":"Gherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca D","family":"Buzoianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00516-X","article-title":"Hearing loss prevalence and years lived with disability, 1990-2019: findings from the Global Burden of Disease Study 2019","volume":"397","year":"2021","unstructured":"Hearing loss prevalence and years lived with disability, 1990-2019. findings from the Global Burden of Disease Study 2019. Lancet. 2021, 397:996-1009. 10.1016\/S0140-6736(21)00516-X","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston G","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, et al.. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020, 396:413-46. 10.1016\/S0140-6736(20)30367-6","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7794384","article-title":"Recent advances and future research directions for hearing loss treatment based on nanoparticles","volume":"2022","author":"Dindelegan MG","year":"2022","unstructured":"Dindelegan MG, Blebea C, Perde-Schrepler M, Buzoianu AD, Maniu AA. Recent advances and future research directions for hearing loss treatment based on nanoparticles. J Nanomater. 2022, 2022:7794384. 10.1155\/2022\/7794384","journal-title":"J Nanomater"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202012010","article-title":"Hearing loss","volume":"173","author":"Nieman CL","year":"2020","unstructured":"Nieman CL, Oh ES. Hearing loss. Ann Intern Med. 2020, 173:ITC81-96. 10.7326\/AITC202012010","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/20786204.2013.10874377","article-title":"An overview of pharmacotherapy-induced ototoxicity","volume":"55","author":"Schellack N","year":"2013","unstructured":"Schellack N, Lecturer S, Naude A, Pathology M, Lecturer S. An overview of pharmacotherapy-induced ototoxicity. S Afr Fam Pract. 2013, 55:357-65. 10.1080\/20786204.2013.10874377","journal-title":"S Afr Fam Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286616","article-title":"Mechanisms involved in ototoxicity","volume":"32","author":"Steyger PS","year":"2011","unstructured":"Steyger PS. Mechanisms involved in ototoxicity. Semin Hear. 2011, 32:217-28. 10.1055\/s-0031-1286616","journal-title":"Semin Hear"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2021.03.008","article-title":"Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies","volume":"163","author":"Tang Q","year":"2021","unstructured":"Tang Q, Wang X, Jin H, et al.. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies. Eur J Pharm Biopharm. 2021, 163:60-71. 10.1016\/j.ejpb.2021.03.008","journal-title":"Eur J Pharm Biopharm"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2022.102203","article-title":"Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis","volume":"79","author":"Dillard LK","year":"2022","unstructured":"Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis. Cancer Epidemiol. 2022, 79:102203. 10.1016\/j.canep.2022.102203","journal-title":"Cancer Epidemiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/toxics3030268","article-title":"Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies","volume":"3","author":"Callejo A","year":"2015","unstructured":"Callejo A, Sed\u00f3-Cabez\u00f3n L, Juan ID, Llorens J. Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies. Toxics. 2015, 3:268-93. 10.3390\/toxics3030268","journal-title":"Toxics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.55551","article-title":"Cisplatin-based chemotherapy: add high-frequency audiometry in the regimen","volume":"46","author":"Arora R","year":"2009","unstructured":"Arora R, Thakur JS, Azad RK, Mohindroo NK, Sharma DR, Seam RK. Cisplatin-based chemotherapy: add high-frequency audiometry in the regimen. Indian J Cancer. 2009, 46:311-7. 10.4103\/0019-509X.55551","journal-title":"Indian J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216545","article-title":"Molecular characteristics of cisplatin-induced ototoxicity and therapeutic interventions","volume":"24","author":"Tan WJ","year":"2023","unstructured":"Tan WJ, Vlajkovic SM. Molecular characteristics of cisplatin-induced ototoxicity and therapeutic interventions. Int J Mol Sci. 2023, 24:10.3390\/ijms242216545","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00999","article-title":"Current strategies to combat cisplatin-induced ototoxicity","volume":"11","author":"Yu D","year":"2020","unstructured":"Yu D, Gu J, Chen Y, Kang W, Wang X, Wu H. Current strategies to combat cisplatin-induced ototoxicity. Front Pharmacol. 2020, 11:999. 10.3389\/fphar.2020.00999","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0b013e31818599d5","article-title":"Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections","volume":"29","author":"Hill GW","year":"2008","unstructured":"Hill GW, Morest DK, Parham K. Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol. 2008, 29:1005-11. 10.1097\/MAO.0b013e31818599d5","journal-title":"Otol Neurotol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03574-9","article-title":"Local inner-ear drug delivery and pharmacokinetics","volume":"10","author":"Salt AN","year":"2005","unstructured":"Salt AN, Plontke SK. Local inner-ear drug delivery and pharmacokinetics. Drug Discov Today. 2005, 10:1299-306. 10.1016\/S1359-6446(05)03574-9","journal-title":"Drug Discov Today"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams DM","year":"2018","unstructured":"Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018, 63:655-70. 10.4187\/respcare.06314","journal-title":"Respir Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2018.01.020","article-title":"Evaluation of a transtympanic delivery system in Mus musculus for extended release steroids","volume":"126","author":"Dormer NH","year":"2019","unstructured":"Dormer NH, Nelson-Brantley J, Staecker H, Berkland CJ. Evaluation of a transtympanic delivery system in Mus musculus for extended release steroids. Eur J Pharm Sci. 2019, 126:3-10. 10.1016\/j.ejps.2018.01.020","journal-title":"Eur J Pharm Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000322504","article-title":"Distribution of dexamethasone and preservation of inner ear function following intratympanic delivery of a gel-based formulation","volume":"16","author":"Salt AN","year":"2011","unstructured":"Salt AN, Hartsock J, Plontke S, Lebel C, Piu F. Distribution of dexamethasone and preservation of inner ear function following intratympanic delivery of a gel-based formulation. Audiol Neurootol. 2011, 16:323-35. 10.1159\/000322504","journal-title":"Audiol Neurootol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/gels8080483","article-title":"Biopolymer lipid hybrid microcarrier for transmembrane inner ear delivery of dexamethasone","volume":"8","author":"Dindelegan MG","year":"2022","unstructured":"Dindelegan MG, Pa\u0219cal\u0103u V, Suciu M, et al.. Biopolymer lipid hybrid microcarrier for transmembrane inner ear delivery of dexamethasone. Gels. 2022, 8:10.3390\/gels8080483","journal-title":"Gels"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/app.49002","article-title":"Bovine serum albumin gel\/polyelectrolyte complex of hyaluronic acid and chitosan based microcarriers for Sorafenib targeted delivery","volume":"137","author":"Pa\u015fcal\u0103u V","year":"2020","unstructured":"Pa\u015fcal\u0103u V, Tertis M, Pall E, et al.. Bovine serum albumin gel\/polyelectrolyte complex of hyaluronic acid and chitosan based microcarriers for Sorafenib targeted delivery. J Appl Polym Sci. 2020, 137:e49002. 10.1002\/app.49002","journal-title":"J Appl Polym Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2020.107893","article-title":"The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents","volume":"388","author":"Perde-Schrepler M","year":"2020","unstructured":"Perde-Schrepler M, Fischer-Fodor E, Virag P, et al.. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents. Hear Res. 2020, 388:107893. 10.1016\/j.heares.2020.107893","journal-title":"Hear Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11948-015-9659-8","article-title":"The three rs of animal research: what they mean for the institutional animal care and use committee and why","volume":"22","author":"Curzer HJ","year":"2016","unstructured":"Curzer HJ, Perry G, Wallace MC, Perry D. The three rs of animal research: what they mean for the institutional animal care and use committee and why. Sci Eng Ethics. 2016, 22:549-65. 10.1007\/s11948-015-9659-8","journal-title":"Sci Eng Ethics"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2012.04.005","article-title":"A comparison of the effects of isoflurane and ketamine anesthesia on auditory brainstem response (ABR) thresholds in rats","volume":"287","author":"Ruebhausen M","year":"2012","unstructured":"Ruebhausen M, Brozoski T, Bauer C. A comparison of the effects of isoflurane and ketamine anesthesia on auditory brainstem response (ABR) thresholds in rats. Hear Res. 2012, 287:25-9. 10.1016\/j.heares.2012.04.005","journal-title":"Hear Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2012.05.010","article-title":"Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs","volume":"40","author":"Shafik AG","year":"2013","unstructured":"Shafik AG, Elkabarity RH, Thabet MT, Soliman NB, Kalleny NK. Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs. Auris Nasus Larynx. 2013, 40:51-60. 10.1016\/j.anl.2012.05.010","journal-title":"Auris Nasus Larynx"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/0145561319874311","article-title":"Efficacy of 2 different intratympanic steroid regimen on prevention of cisplatin ototoxicity: an experimental study","volume":"100","author":"Ta\u015f BM","year":"2021","unstructured":"Ta\u015f BM, \u015eim\u015fek G, Azman M, K\u0131l\u0131\u00e7 R. Efficacy of 2 different intratympanic steroid regimen on prevention of cisplatin ototoxicity: an experimental study. Ear Nose Throat J. 2021, 100:417-22. 10.1177\/0145561319874311","journal-title":"Ear Nose Throat J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2019.03.021","article-title":"Prevention of cisplatin-induced hearing loss by extended release fluticasone propionate intracochlear implants","volume":"121","author":"Pierstorff E","year":"2019","unstructured":"Pierstorff E, Yang WW, Chen YA, Cheung S, Kalinec F, Slattery WH. Prevention of cisplatin-induced hearing loss by extended release fluticasone propionate intracochlear implants. Int J Pediatr Otorhinolaryngol. 2019, 121:157-63. 10.1016\/j.ijporl.2019.03.021","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/audiolres12050047","article-title":"The effect of pluronic-coated gold nanoparticles in hearing preservation following cochlear implantation-pilot study","volume":"12","author":"Blebea CM","year":"2022","unstructured":"Blebea CM, Necula V, Potara M, et al.. The effect of pluronic-coated gold nanoparticles in hearing preservation following cochlear implantation-pilot study. Audiol Res. 2022, 12:466-75. 10.3390\/audiolres12050047","journal-title":"Audiol Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2016.02.019","article-title":"HEI-OC1 cells as a model for investigating drug cytotoxicity","volume":"335","author":"Kalinec G","year":"2016","unstructured":"Kalinec G, Thein P, Park C, Kalinec F. HEI-OC1 cells as a model for investigating drug cytotoxicity. Hear Res. 2016, 335:105-17. 10.1016\/j.heares.2016.02.019","journal-title":"Hear Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091464","article-title":"Solid lipid nanoparticles loaded with glucocorticoids protect auditory cells from cisplatin-induced ototoxicity","volume":"8","author":"Cervantes B","year":"2019","unstructured":"Cervantes B, Arana L, Murillo-Cuesta S, Bruno M, Alkorta I, Varela-Nieto I. Solid lipid nanoparticles loaded with glucocorticoids protect auditory cells from cisplatin-induced ototoxicity. J Clin Med. 2019, 8:1464. 10.3390\/jcm8091464","journal-title":"J Clin Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/0194599814524894","article-title":"Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: a randomized controlled study","volume":"150","author":"Marshak T","year":"2014","unstructured":"Marshak T, Steiner M, Kaminer M, Levy L, Shupak A. Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: a randomized controlled study. Otolaryngol Head Neck Surg. 2014, 150:983-90. 10.1177\/0194599814524894","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/AUD.0000000000001119","article-title":"Evaluating the efficacy of intratympanic dexamethasone in protecting against irreversible hearing loss in patients on cisplatin-based cancer treatment: a randomized controlled phase IIIB clinical trial","volume":"43","author":"Moreno I","year":"2022","unstructured":"Moreno I, Belinchon A. Evaluating the efficacy of intratympanic dexamethasone in protecting against irreversible hearing loss in patients on cisplatin-based cancer treatment: a randomized controlled phase IIIB clinical trial. Ear Hear. 2022, 43:676-84. 10.1097\/AUD.0000000000001119","journal-title":"Ear Hear"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/307272-hydrogel-matrix-containing-microcarriers-for-dexamethasone-delivery-to-protect-against-cisplatin-induced-hearing-loss","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:17:28Z","timestamp":1728487048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/307272-hydrogel-matrix-containing-microcarriers-for-dexamethasone-delivery-to-protect-against-cisplatin-induced-hearing-loss"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.71142","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,9]]}}}